Globus Medical Value Chain Analysis
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Go Beyond the Preview – Access the Full Value Chain Analysis
This Globus Medical Value Chain Analysis helps you quickly understand how the company creates value across its support and primary activities in one structured framework. This page already shows a real preview of the analysis, so you can review the actual content before buying. Purchase the full version to get the complete ready-to-use report.
Support Activities
Firm Infrastructure
Globus Medical depends on centralized finance, compliance, quality, and integration systems to run a platform that spans implants, robotics, and more than 1 regulatory regime. The 2023 NuVasive merger made this even more important, because the business now manages a much larger operating base and a 2025 revenue run rate near $2.5 billion.
Firm infrastructure helps standardize controls, track product quality, and align reporting across surgical and spine lines. It also supports faster integration after the merger, which matters when the product mix is complex and recall or compliance errors can hit margin and trust fast.
Human Resource Management
Globus Medical needs engineers, manufacturing staff, clinical specialists, and direct sales teams with deep spine knowledge. In 2025, its larger post-NuVasive field force makes training and retention even more important, because better OR execution and faster product adoption lift both surgeon trust and repeat use.
Human resource management also supports quality and output in a business that depends on precise implant design and clean production. Keeping experienced staff lowers rework, improves coordination across hospitals, and helps Globus Medical defend its roughly $2.5 billion revenue base.
Technology Development
R&D is Globus Medical's main edge: its 2025 work in device engineering, software, and robotics keeps raising surgical precision and supports premium pricing.
The company uses tech development to widen its implant and enabling-technology portfolio, which helps it compete in spine and trauma. That mix matters because Globus Medical reported FY2025 revenue growth and kept spending on product innovation to protect share.
Robotics and navigation also make procedures more consistent, which can improve surgeon adoption and hospital use. In plain terms, Globus Medical turns R&D into both better outcomes and stronger margins.
Procurement
Globus Medical's procurement team sources medical-grade metals, polymers, electronics, sensors, and precision machining services from qualified suppliers, because one weak input can affect implant quality and device performance.
In a tightly regulated market, strong procurement protects supply continuity, supports traceability, and helps control cost while meeting strict quality and compliance needs.
Globus Medical's Support Backbone Keeps Scale, Quality, and Trust Intact
Globus Medical's support activities are built to keep a larger, post-NuVasive business tight on controls, quality, and compliance. In 2025, that matters more as revenue runs near $2.5 billion and any failure in sourcing, training, or reporting can hit margins and surgeon trust fast.
| Support activity | 2025 role |
|---|---|
| Infrastructure, HR, R&D, procurement | Controls, talent, innovation, supply continuity |
What is included in the product
Detailed Word Document
Editable Excel File
Primary Activities
Inbound Logistics
Globus Medical sources regulated materials, implants, and robotic parts through tightly controlled supplier channels, because missing one part can delay a scheduled procedure. In fiscal 2025, the business scale was large, with revenue near $2.7 billion, so inbound planning and quality checks matter for service levels and inventory turns. Tight control of receiving, traceability, and safety stock helps keep surgeons supplied on time while limiting stockouts and excess inventory.
Operations
Globus Medical designs, manufactures, assembles, tests, and validates implants, instruments, and enabling systems in-house, so it keeps tighter control over quality and product changes. That setup shortens feedback loops, cuts rework risk, and supports gross margin discipline; in fiscal 2025, Globus Medical also kept scaling its integrated spine portfolio after the NuVasive deal. Its operations are built to protect consistency and speed launches.
Outbound Logistics
Globus Medical ships case-ready inventory through controlled warehouses, consignment sets, and direct delivery, so trays reach hospitals when spine teams need them. Outbound logistics is high-stakes because a missing or late tray can delay or cancel a case, and each missed surgery can hit both revenue and surgeon trust. In fiscal 2025, the priority stays the same: fast, accurate fulfillment with tight inventory control and traceability.
Marketing and Sales
Globus Medical sells mainly through a direct field force that works with surgeons, hospitals, and buying teams, so it can push account wins and grow implant use fast. Its sales model leans on clinical education, live demos, and peer-to-peer selling, which helps lower adoption friction in spine and trauma cases.
This approach supports a high-touch channel and protects pricing when systems compare vendors.
Service
In FY2025, Globus Medical's service layer for robotic and enabling technologies covered case support, technical help, training, and maintenance, so surgeons can keep using the platform with less downtime. Post-sale service helps protect the installed base and supports repeat orders by making the workflow stickier after the initial sale. This matters because recurring support tied to capital systems can be a strong retention tool in spine surgery.
Globus Medical's 2025 Playbook: Make, Ship, Support
Globus Medical's primary activities in fiscal 2025 centered on making, testing, and delivering spine and trauma implants plus robotic tools, with direct sales, clinical training, and case support driving adoption.
Its integrated model kept quality control tight across production and fulfillment, which helped support a 2025 revenue base of about $2.7 billion.
Fast outbound logistics and post-sale service mattered most because late trays or downtime can delay surgery and weaken surgeon loyalty.
| 2025 focus | Key point |
|---|---|
| Primary activities | Make, sell, ship, support |
| Revenue | About $2.7 billion |
Preview the Actual Deliverable
Globus Medical Reference Sources
This is the actual Globus Medical Value Chain Analysis document you'll receive upon purchase – no surprises, just the full professional version.
The preview below is taken directly from the complete report, so what you see here is exactly what you'll get after checkout.
Purchase now to unlock the full, detailed Globus Medical Value Chain Analysis in its entirety.
Frequently Asked Questions
Technology development and direct surgeon support drive it most. Globus Medical's value chain is organized into 4 support activities and 5 primary activities, but the strongest value creation comes from spine R&D, robotics, and clinical education. The 2023 NuVasive merger also widened product breadth and gave Globus Medical more scale across implants, navigation, and field support.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site - including articles or product references - constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.